Exponent, Inc. (NASDAQ:EXPO) recently reported financial results for the third quarter ended October 1, 2010. For the third quarter of 2010, revenues before reimbursements increased 12% to $56,906,000, as compared to $50,666,000 in the third quarter of 2009.
Exponent, Inc., together with its subsidiaries, provides science and engineering consulting services in the United States and internationally.
Hiru Corporation (PINK SHEETS:HIRU) (http://www.hirucorporation.com) subsidiary Jiangxi Shaungshi Pharmaceutical Co., Ltd (Shaungshi AHP) launched the Jiangxi Shaungshi Biological Medicines Institute.
Shuangshi AHP is currently researching several new veterinary drugs for development within the next two years. The company launched this new institute to strengthen and speed up the research and development processes. The Institute will allow the company a better focus and concentration of its talent in bio-tech development and research. Shaungshi AHP has elected Li Rui to be director of the institute.
Hiru Corporation intends to continue its work in the development, production and marketing of both well-established and new veterinary drugs, and nutritional additives (amino acids, vitamins, trace elements, etc.) for the Chinese market.
The company is pleased with this development and looks forward to future growth.
PWRM, Power 3 Medical Products Inc., PWRM.OB has signed a definitive agreement recently to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger.
The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.
Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.
Power3 Medical Hits a Grand Slam at ICAD With Four Alzheimer’s Poster Presentations
Power3 Medical Products, Inc. announced a few weeks ago that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3’s President and Chief Scientific Officer.
“It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
About the Company
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.
These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Redwood Trust, Inc. (NYSE:RWT) recently announced its third quarter 2010 earnings through the publication of an earnings press release. In addition, Redwood Trust recently published The Redwood Review for the third quarter 2010. Both the earnings press release and The Redwood Review were filed with the Securities and Exchange Commission recently on Form 8-K.
Redwood Trust, Inc., a financial institution, together with its subsidiaries, invests in, finances, and manages residential and commercial real estate loans and securities.
KVH Industries, Inc. (NASDAQ:KVHI) recently announced a new distribution agreement with Furuno Electric Co., Ltd. for KVH's mini-VSAT BroadbandSM service. Under the terms of this arrangement, Furuno will begin marketing and selling mini-VSAT Broadband airtime service and supporting equipment along with a compatible 1-meter antenna system on a global basis through its established distributor and dealer channels.
KVH Industries, Inc., and its subsidiaries are leading providers of in-motion satellite TV and communication systems, having designed, manufactured, and sold more than 150,000 mobile satellite antennas for applications on vessels, vehicles, and aircraft.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM). Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (OTCPK:HIRU).